Plenaxis Uses, Dosage, Side Effects and more
Synthetic decapeptide antagonist to gonadotropin releasing hormone (GnRH). It is marketed by Praecis Pharmaceuticals as Plenaxis. Praecis announced in June 2006 that it was voluntarily withdrawing the drug from the market.
Used in the palliative treatment of advanced prostate cancer. Plenaxis is a luteinizing hormone agonist that results in suppression of testicular or follicular steroidogenesis.
| Trade Name | Plenaxis |
| Availability | Discontinued |
| Generic | Abarelix |
| Abarelix Other Names | Abarelix |
| Related Drugs | estradiol, Premarin, Xtandi, Casodex, Zytiga, Lynparza |
| Type | |
| Formula | C72H95ClN14O14 |
| Weight | Average: 1416.09 Monoisotopic: 1414.6840715 |
| Protein binding | 96-99% |
| Groups | Approved, Investigational, Withdrawn |
| Therapeutic Class | |
| Manufacturer | EuroCept |
| Available Country | United States, Netherlands, |
| Last Updated: | January 7, 2025 at 1:49 am |
Uses
For palliative treatment of advanced prostate cancer.
How Plenaxis works
Plenaxis binds to the gonadotropin releasing hormone receptor and acts as a potent inhibitor of gonadotropin secretion.
Toxicity
The maximum tolerated dose of abarelix has not been determined. The maximum dose used in clinical studies was 150 mg. There have been no reports of accidental overdose with abarelix.
Drug Interaction
Minor: sulfamethoxazole / trimethoprim, sulfamethoxazole / trimethoprimUnknown: acetaminophen, acetaminophen, aspirin, aspirin, alprazolam, alprazolam, pseudoephedrine / triprolidine, pseudoephedrine / triprolidine, carboplatin, carboplatin, clotrimazole, clotrimazole, indium pentetate in-111, indium pentetate in-111
Elimination Route
Following IM administration of 100 mg, abarelix is absorbed slowly with a mean peak concentration of 43.4 ng/mL observed approximately 3 days after the injection.
Half Life
13.2 ± 3.2 days
